Practices Core
Practices Core
批准号:
10793944
负责人:
William Paul Duprex
金额:
$72.71万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-18 至 2028-07-31
关键词:
AccelerationAccountabilityAdministratorAnimalsBiologicalBiologyBioterrorismCertificationComplexCreativenessDisciplineElementsEmergency SituationEmerging Communicable DiseasesEngineeringEnsureEnvironmental HealthEquipment and supply inventoriesEventEvolutionGoalsHuman ResourcesIn VitroIndustryInfectionInfrastructureInternationalInterventionLaboratoriesLaboratory AnimalsLaboratory AssistantLeadMentorsMissionMonitorNational Institute of Allergy and Infectious DiseaseOutcomePathogenesisProceduresReference StandardsRegulationReportingReproducibilityResearchResearch PersonnelRestRunningSafetyScientistSecureServicesSideStandardizationSupervisionSystemToxinTrainingTubeUniversitiesVaccine ResearchVeterinariansViralVisionWorkanimal resourcebiodefensebiosafety level 3 facilitybiosecuritycohortdata integritydata qualitydata quality/integrityemerging pathogenequipment traininghands on instructionin vivomedical countermeasuremembernoveloperationpandemic diseasepandemic preparednesspathogenpreclinical developmentprogramsquality assuranceresearch facilityresponsetransmission process
中文摘要
实践核心
摘要:
大学疫苗研究中心(CVR)内的区域生物遏制实验室(RBL)
匹兹堡是感染生物学的生物安全3级(BSL-3)枢纽。RBL的使命有三个方面,即
致力于病原体的出现、进化和宿主间的传播,以研究肺炎的发病机制
新出现的传染病和加快临床前新干预措施和医疗的发展
预防大流行和生物防御的对策。我们的愿景是成为全球公认的、高度-
由感染生物学家组成的协作、创新和前瞻的团队,准备应对新出现的
国家和国际两级的生物威胁。整个工厂都在
选择试剂和毒素(DSAT)。它汇集了来自不同学科的感染生物学家和临床医生。
他们需要BSL-3和动物(A)BSL-3设施来进行广泛的病毒和细菌研究项目。
生物遏制工作操作复杂、基础设施密集、监管全面。正在运行
BSL-3实验室安全、安全、成功地要求有一个组织严密、高度集成的
由管理员、科学家、生物安全/生物安全专业人员、工程师/设施工作人员和
兽医/动物园技术人员。这在多病原体、多用户研究设施中尤其重要
研究标准和筛选试剂BSL-3病原菌。实践核心将支持的所有基本功能
RBL使科学计划能够得到严格管理,并确保可重现的总体数据完整性
结果。它将为新的RBL调查员提供必要的理论和实践培训,并
他们的团队希望在BSL-3和ABSL-3生物遏制方面工作。它将提供生物安全和生物保障
支持并保证设施符合注册的第1级选择代理的所有当前合规性规定
实验室。为匹兹堡的RBL提供技术和支持将确保我们准备好应对
任何国家在发生另一场大流行或
生物恐怖袭击。支持这群BSL-3科学家,他们可以转而在
紧急情况下,一定会有回报的。
英文摘要
PRACTICES CORE
ABSTRACT:
The Regional Biocontainment Laboratory (RBL) within the Center for Vaccine Research (CVR) at the University
of Pittsburgh is the biosafety level-3 (BSL-3) hub for infection biology. The mission of the RBL is threefold, to
work on pathogen emergence, evolution and host-to-host transmission, to study the pathogenesis of
emerging infectious diseases and to accelerate pre-clinical development of novel interventions and medical
countermeasures for pandemic preparedness and biodefense. Our vision is to be a globally recognized, highly-
collaborative, creative and forward-facing team of infection biologists who are poised to respond to emerging
biological threats both at the national and international level. The entire facility is registered with the Division of
Select Agents and Toxins (DSAT). It brings together infection biologists and clinicians from a variety of disciplines
who require BSL-3 and animal (A)BSL-3 facilities for their wide ranging viral and bacterial research programs.
Biocontainment work is operationally complex, infrastructure-dense, and comprehensively regulated. Running
BSL-3 laboratories safely, securely and successfully demands having a well-organized and highly integrated
team of administrators, scientists, biosafety/biosecurity professionals, engineers/facilities staff and
veterinarians/zootechnical staff. This is especially important in multi-pathogen, multi-user research facilities that
study standard and select agent BSL-3 pathogens. The Practices Core will support all the basic functions of the
RBL enabling scientific programs to be rigorously managed and ensuring overall data integrity for reproducible
outcomes. It will provide the requisite theoretical and practical trainings to onboard new RBL Investigators and
their teams who wish to work in BSL-3 and ABSL-3 biocontainment. It will provide biosafety and biosecurity
support and guarantee the facility meets all current compliance regulations for Tier 1 select agent registered
laboratories. Provision of technical and support for the RBL in Pittsburgh will ensure we are ready to respond to
any national response to a range of emerging infectious diseases in the event of another pandemic or
bioterrorism attack. Supporting this cohort of BSL-3 scientists, who can pivot to work on new pathogens in an
emergency, is certain to pay dividends.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Operations Core
-
批准号:10793943
-
项目类别:
-
资助金额:$98.46万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Pitt RBL
-
批准号:10793942
-
项目类别:
-
资助金额:$287.02万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Integrated Services Core
-
批准号:10793945
-
项目类别:
-
资助金额:$115.86万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
-
批准号:10631339
-
项目类别:
-
资助金额:$332.97万
-
财政年份:2022
-
负责人:William Paul Duprex
-
依托单位:
Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization
-
批准号:10444442
-
项目类别:
-
资助金额:$76.9万
-
财政年份:2022
-
负责人:William Paul Duprex
-
依托单位:
Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
-
批准号:10394474
-
项目类别:
-
资助金额:$333.0万
-
财政年份:2021
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8664340
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8504483
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:9064740
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8852530
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:9278078
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8307628
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2011
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8461424
-
项目类别:
-
资助金额:$10.78万
-
财政年份:2006
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8709528
-
项目类别:
-
资助金额:$2.92万
-
财政年份:--
-
负责人:William Paul Duprex
-
依托单位:
海外基金